Itraconazole for COVID-19 : preclinical studies and a proof-of-concept randomized clinical trial
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved..
BACKGROUND: The antifungal drug itraconazole exerts in vitro activity against SARS-CoV-2 in Vero and human Caco-2 cells. Preclinical and clinical studies are required to investigate if itraconazole is effective for the treatment and/or prevention of COVID-19.
METHODS: Due to the initial absence of preclinical models, the effect of itraconazole was explored in a clinical, proof-of-concept, open-label, single-center study, in which hospitalized COVID-19 patients were randomly assigned to standard of care with or without itraconazole. Primary outcome was the cumulative score of the clinical status until day 15 based on the 7-point ordinal scale of the World Health Organization. In parallel, itraconazole was evaluated in a newly established hamster model of acute SARS-CoV-2 infection and transmission, as soon as the model was validated.
FINDINGS: In the hamster acute infection model, itraconazole did not reduce viral load in lungs, stools or ileum, despite adequate plasma and lung drug concentrations. In the transmission model, itraconazole failed to prevent viral transmission. The clinical trial was prematurely discontinued after evaluation of the preclinical studies and because an interim analysis showed no signal for a more favorable outcome with itraconazole: mean cumulative score of the clinical status 49 vs 47, ratio of geometric means 1.01 (95% CI 0.85 to 1.19) for itraconazole vs standard of care.
INTERPRETATION: Despite in vitro activity, itraconazole was not effective in a preclinical COVID-19 hamster model. This prompted the premature termination of the proof-of-concept clinical study.
FUNDING: KU Leuven, Research Foundation - Flanders (FWO), Horizon 2020, Bill and Melinda Gates Foundation.
| Errataetall: |
ErratumIn: EBioMedicine. 2021 Jul;69:103454. - PMID 34186486 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
EBioMedicine - 66(2021) vom: 22. Apr., Seite 103288 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
304NUG5GF4 |
|---|
| Anmerkungen: |
Date Completed 17.05.2021 Date Revised 31.03.2024 published: Print-Electronic ErratumIn: EBioMedicine. 2021 Jul;69:103454. - PMID 34186486 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ebiom.2021.103288 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323084532 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323084532 | ||
| 003 | DE-627 | ||
| 005 | 20240331233025.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ebiom.2021.103288 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1358.xml |
| 035 | |a (DE-627)NLM323084532 | ||
| 035 | |a (NLM)33752127 | ||
| 035 | |a (PII)S2352-3964(21)00081-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liesenborghs, Laurens |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Itraconazole for COVID-19 |b preclinical studies and a proof-of-concept randomized clinical trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.05.2021 | ||
| 500 | |a Date Revised 31.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: EBioMedicine. 2021 Jul;69:103454. - PMID 34186486 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: The antifungal drug itraconazole exerts in vitro activity against SARS-CoV-2 in Vero and human Caco-2 cells. Preclinical and clinical studies are required to investigate if itraconazole is effective for the treatment and/or prevention of COVID-19 | ||
| 520 | |a METHODS: Due to the initial absence of preclinical models, the effect of itraconazole was explored in a clinical, proof-of-concept, open-label, single-center study, in which hospitalized COVID-19 patients were randomly assigned to standard of care with or without itraconazole. Primary outcome was the cumulative score of the clinical status until day 15 based on the 7-point ordinal scale of the World Health Organization. In parallel, itraconazole was evaluated in a newly established hamster model of acute SARS-CoV-2 infection and transmission, as soon as the model was validated | ||
| 520 | |a FINDINGS: In the hamster acute infection model, itraconazole did not reduce viral load in lungs, stools or ileum, despite adequate plasma and lung drug concentrations. In the transmission model, itraconazole failed to prevent viral transmission. The clinical trial was prematurely discontinued after evaluation of the preclinical studies and because an interim analysis showed no signal for a more favorable outcome with itraconazole: mean cumulative score of the clinical status 49 vs 47, ratio of geometric means 1.01 (95% CI 0.85 to 1.19) for itraconazole vs standard of care | ||
| 520 | |a INTERPRETATION: Despite in vitro activity, itraconazole was not effective in a preclinical COVID-19 hamster model. This prompted the premature termination of the proof-of-concept clinical study | ||
| 520 | |a FUNDING: KU Leuven, Research Foundation - Flanders (FWO), Horizon 2020, Bill and Melinda Gates Foundation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antivirals | |
| 650 | 4 | |a drug repurposing | |
| 650 | 4 | |a itraconazole | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Itraconazole |2 NLM | |
| 650 | 7 | |a 304NUG5GF4 |2 NLM | |
| 700 | 1 | |a Spriet, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Jochmans, Dirk |e verfasserin |4 aut | |
| 700 | 1 | |a Belmans, Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Gyselinck, Iwein |e verfasserin |4 aut | |
| 700 | 1 | |a Teuwen, Laure-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Ter Horst, Sebastiaan |e verfasserin |4 aut | |
| 700 | 1 | |a Dreesen, Erwin |e verfasserin |4 aut | |
| 700 | 1 | |a Geukens, Tatjana |e verfasserin |4 aut | |
| 700 | 1 | |a Engelen, Matthias M |e verfasserin |4 aut | |
| 700 | 1 | |a Landeloos, Ewout |e verfasserin |4 aut | |
| 700 | 1 | |a Geldhof, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Ceunen, Helga |e verfasserin |4 aut | |
| 700 | 1 | |a Debaveye, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Vandenberk, Bert |e verfasserin |4 aut | |
| 700 | 1 | |a Van der Linden, Lorenz |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobs, Sofie |e verfasserin |4 aut | |
| 700 | 1 | |a Langendries, Lana |e verfasserin |4 aut | |
| 700 | 1 | |a Boudewijns, Robbert |e verfasserin |4 aut | |
| 700 | 1 | |a Do, Thuc Nguyen Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Chiu, Winston |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xinyu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Weynand, Birgit |e verfasserin |4 aut | |
| 700 | 1 | |a Vanassche, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Devos, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Meyfroidt, Geert |e verfasserin |4 aut | |
| 700 | 1 | |a Janssens, Wim |e verfasserin |4 aut | |
| 700 | 1 | |a Vos, Robin |e verfasserin |4 aut | |
| 700 | 1 | |a Vermeersch, Pieter |e verfasserin |4 aut | |
| 700 | 1 | |a Wauters, Joost |e verfasserin |4 aut | |
| 700 | 1 | |a Verbeke, Geert |e verfasserin |4 aut | |
| 700 | 1 | |a De Munter, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Kaptein, Suzanne J F |e verfasserin |4 aut | |
| 700 | 1 | |a Rocha-Pereira, Joana |e verfasserin |4 aut | |
| 700 | 1 | |a Delang, Leen |e verfasserin |4 aut | |
| 700 | 1 | |a Van Wijngaerden, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Neyts, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Verhamme, Peter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t EBioMedicine |d 2014 |g 66(2021) vom: 22. Apr., Seite 103288 |w (DE-627)NLM244581355 |x 2352-3964 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2021 |g day:22 |g month:04 |g pages:103288 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ebiom.2021.103288 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2021 |b 22 |c 04 |h 103288 | ||